Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 35

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
 combination with one or more businesses.
We intend to effectuate our initial business combination using cash derived from the proceeds of the Initial Public Offering (as defined
below) and the sale of the Private Placement Units (as defined below), our shares, debt or a combination of cash, shares and debt.

We
expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete
an initial business combination will be successful.

While
we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses
in the pharmaceutical industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all
of the risks associated with early stage and emerging growth companies.

The
registration statement for the Company’s initial public offering (the “IPO” or “Initial Public Offering”)
was declared effective on January 27, 2025. On January 29, 2025, we consummated our Initial Public Offering of 20,000,000 units (the
“Units”). Each Unit consists of one ordinary share, $0.0001 par value (“ordinary share”) and one right to receive
one-eighth (1/8) of one ordinary share upon the consummation of an initial business combination. The Units were sold at an offering price
of $10.00 per unit, generating gross proceeds, before expenses, of $200,000,000. We granted the underwriters a 45-day option to purchase
up to 3,000,000 additional Units to cover over-allotments, if any.

19

Simultaneously
with the closing of the IPO, we consummated the private placement with Drugs Made In America Acquisition LLC, our sponsor, of 400,000
units (the “Private Placement Units”) at a price of $10.00 per unit, for $4,000,000. The Private Placement Units are identical
to the Units sold in the IPO, except that the Private Placement Units, including the underlying securities, may not, subject to certain
limited exceptions, be transferable, assignable or salable by the sponsor until the earlier of: (i) with respect to 50% of the Private
Placement Units, the earlier of six months after the date of the consummation of our initial business combination and the date on which
the closing price of our ordinary shares equals or exceeds $12.50